[{"orgOrder":0,"company":"Melt Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Midazolam","moa":"GABA A receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Melt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Melt Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Melt Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"ImprimisRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Midazolam","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"ImprimisRx","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Troche","sponsorNew":"ImprimisRx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ImprimisRx \/ Not Applicable"},{"orgOrder":0,"company":"Melt Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Midazolam","moa":"GABA A receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Melt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Melt Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Melt Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Melt Pharmaceuticals","sponsor":"Harrow Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Financing","leadProduct":"Midazolam","moa":"GABA A receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Melt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Melt Pharmaceuticals \/ Harrow Health","highestDevelopmentStatusID":"6","companyTruncated":"Melt Pharmaceuticals \/ Harrow Health"},{"orgOrder":0,"company":"Brain Therapeutics","sponsor":"Neuraxpharm","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Midazolam","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"Brain Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oromucosal Solution","sponsorNew":"Brain Therapeutics \/ Neuraxpharm Group","highestDevelopmentStatusID":"12","companyTruncated":"Brain Therapeutics \/ Neuraxpharm Group"},{"orgOrder":0,"company":"Melt Pharmaceuticals","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"GABA A receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Melt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Melt Pharmaceuticals \/ Catalent","highestDevelopmentStatusID":"8","companyTruncated":"Melt Pharmaceuticals \/ Catalent"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Neuraxpharm","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Acquisition","leadProduct":"Midazolam","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Takeda Pharmaceutical \/ Neuraxpharm Group","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pharmaceutical \/ Neuraxpharm Group"},{"orgOrder":0,"company":"Neuraxpharm","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Midazolam","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"Neuraxpharm","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oromucosal","sponsorNew":"Neuraxpharm \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Neuraxpharm \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Crossject","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Midazolam","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"Crossject","amount2":0.059999999999999998,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.059999999999999998,"dosageForm":"Intramuscular injection","sponsorNew":"Crossject \/ BARDA","highestDevelopmentStatusID":"12","companyTruncated":"Crossject \/ BARDA"},{"orgOrder":0,"company":"Rafa","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Midazolam","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"Rafa","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Rafa \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Rafa \/ Not Applicable"},{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"EDP-235","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enanta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Enanta Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enanta Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Melt Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Midazolam","moa":"GABA A receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Melt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Melt Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Melt Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Crossject","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Midazolam","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"Crossject","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Crossject \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Crossject \/ Not Applicable"},{"orgOrder":0,"company":"Harrow","sponsor":"iOR Partners","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Midazolam","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Harrow","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Harrow \/ iOR Partners","highestDevelopmentStatusID":"12","companyTruncated":"Harrow \/ iOR Partners"},{"orgOrder":0,"company":"Melt Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Midazolam","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Melt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Melt Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Melt Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Crossject","sponsor":"AFT Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Midazolam","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Crossject","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Crossject \/ AFT Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Crossject \/ AFT Pharmaceuticals"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Melt Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Midazolam","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Catalent Pharma Solutions \/ Melt Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Catalent Pharma Solutions \/ Melt Pharmaceuticals"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Crossject","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"Midazolam","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Syneos Health \/ Crossject","highestDevelopmentStatusID":"12","companyTruncated":"Syneos Health \/ Crossject"},{"orgOrder":0,"company":"Crossject","sponsor":"Heights Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Financing","leadProduct":"Midazolam","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Crossject","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Crossject \/ Heights Capital Management","highestDevelopmentStatusID":"12","companyTruncated":"Crossject \/ Heights Capital Management"},{"orgOrder":0,"company":"Crossject","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Midazolam","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Crossject","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Crossject \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Crossject \/ Undisclosed"},{"orgOrder":0,"company":"Melt Pharmaceuticals","sponsor":"Newbridge Securities Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Series B Financing","leadProduct":"Midazolam","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Melt Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.02,"dosageForm":"Tablet","sponsorNew":"Melt Pharmaceuticals \/ Newbridge Securities Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Melt Pharmaceuticals \/ Newbridge Securities Corporation"},{"orgOrder":0,"company":"Crossject","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"Midazolam","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Crossject","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Crossject \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Crossject \/ Undisclosed"},{"orgOrder":0,"company":"Crossject","sponsor":"Gemmes Venture","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"Midazolam","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Crossject","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Crossject \/ Gemmes Venture","highestDevelopmentStatusID":"12","companyTruncated":"Crossject \/ Gemmes Venture"},{"orgOrder":0,"company":"Melt Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Midazolam","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Melt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Melt Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Melt Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Crossject","sponsor":"Bpifrance","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Financing","leadProduct":"Midazolam","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Crossject","amount2":0.01,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Crossject \/ Bpifrance","highestDevelopmentStatusID":"14","companyTruncated":"Crossject \/ Bpifrance"},{"orgOrder":0,"company":"Nura Bio","sponsor":"The Column Group","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Series A Financing","leadProduct":"Caffeine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Nura Bio","amount2":0.14000000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Nura Bio \/ The Column Group","highestDevelopmentStatusID":"14","companyTruncated":"Nura Bio \/ The Column Group"},{"orgOrder":0,"company":"Melt Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Midazolam","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Melt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Melt Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Melt Pharmaceuticals \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for Midazolam

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : MELT-300, a non-intravenous, non-opioid tablet that blends fixed doses of midazolam and ketamine. This medication is designed for procedural sedation during cataract surgery.

                          Brand Name : MELT-300

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          October 10, 2024

                          Lead Product(s) : Midazolam,Ketamine Hydrochloride

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : The financing will support the clinical development of NB-4746, a SARM1 inhibitor currently being evaluated in early-stage trials for the treatment of amyotrophic lateral sclerosis.

                          Brand Name : NB-4746

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          September 17, 2024

                          Lead Product(s) : NB-4746,Caffeine,Midazolam

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : The Column Group

                          Deal Size : $140.0 million

                          Deal Type : Series A Financing

                          blank

                          03

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : The proceeds will support development of crossject's ZENEO® Epinephrine needle-free autoinjector, for treatment of severe allergic reactions (anaphylactic shock).

                          Brand Name : Zeneo

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          July 10, 2024

                          Lead Product(s) : Midazolam

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved

                          Sponsor : Bpifrance

                          Deal Size : $7.4 million

                          Deal Type : Financing

                          blank

                          04

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : MELT-300, a non-intravenous, non-opioid tablet that blends fixed doses of midazolam and ketamine is being investigated for procedural sedation during cataract surgery.

                          Brand Name : MELT-300

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          June 06, 2024

                          Lead Product(s) : Midazolam,Ketamine Hydrochloride

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : The net proceeds will be used to support Crossject’s activities in bringing its Zepizure (midazolam), a short-acting hypnotic-sedative epileptic rescue therapy, to market.

                          Brand Name : Zepizure

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          June 04, 2024

                          Lead Product(s) : Midazolam

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Gemmes Venture

                          Deal Size : $8.2 million

                          Deal Type : Public Offering

                          blank

                          06

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : Under the terms of the agreement, Crossject Zepizure (midazolam) will be commercialized in the European market for the treatment of epileptic seizures.

                          Brand Name : Zepizure

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          May 02, 2024

                          Lead Product(s) : Midazolam

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          07

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : The funding will advance MELT-300, a non-intravenous, non-opioid tablet combining midazolam and ketamine, designed for procedural sedation during cataract surgery.

                          Brand Name : MELT-300

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          April 02, 2024

                          Lead Product(s) : Midazolam,Ketamine Hydrochloride

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Newbridge Securities Corporation

                          Deal Size : $24.0 million

                          Deal Type : Series B Financing

                          blank

                          08

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : The financing aims to support the clinical development of Zepizure (midazolam), a short-acting hypnotic-sedative medication currently undergoing evaluation in patients for epileptic seizures.

                          Brand Name : Zepizure

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          February 27, 2024

                          Lead Product(s) : Midazolam

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Heights Capital Management

                          Deal Size : $12.0 million

                          Deal Type : Financing

                          blank

                          09

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : Under the agreement, Syneos Health will provide support in all pre-launch and launch activities for Zepizure (midazolam), an epileptic rescue therapy for epileptic seizures.

                          Brand Name : Zepizure

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          January 04, 2024

                          Lead Product(s) : Midazolam

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved

                          Sponsor : Crossject

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          10

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : The agreement aims for the commercialization of Crossject's innovative rescue therapy for epileptic seizures Zepizure (midazolam), previously known as ZENEO® Midazolam, in northern Europe covering Germany, the UK, Denmark, Sweden, Finland and Norway.

                          Brand Name : Zepizure

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          December 22, 2023

                          Lead Product(s) : Midazolam

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved

                          Sponsor : Undisclosed

                          Deal Size : $1.0 million

                          Deal Type : Agreement

                          blank